Openbookopenbook
Equity
ORINY
+0.0 · +0.00%
USD · PINK

Orion Oyj ADR(ORINY) Stock Analysis | Healthcare

USD --+0.00%
Reward55Moderate
Risk19Low
75%Data
Strong 26% profit margin · 4.4% dividend yield · Revenue growing 60% YoY
Defensive Anchor
Market Cap:11.42Bn
ⓘ
Reward Rating
55
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
19
Low
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ORINY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ORINY, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Orion Oyj ADR?

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.

ORINY · Verdict

Solid reward · low risk

ORINY stands out on cash flow and profitability, but watch the valuation signal.

Based on 88% data coverage

ORINY · Verdict

What’s working & what to watch

Strengths 4

  • Cash flow89/100

    12% free-cash-flow margin

  • Profitability82/100

    25% net margin · 44% ROE

  • Balance sheet80/100

    Interest covered 160.6×

  • Volatility80/100

    Top decile vs peers

Watchouts 1

  • Valuation24/100

    P/E 32.7×

Model-based scoring. For information only — not financial advice.

What is Orion Oyj ADR?

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 11.42B, and a P/E ratio of 19.3x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (55)

The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

RCDTFLarge Cap / 11.6B market cap
Recordati Industria Chimica e Farmaceutica S.p.A
Compare
CHJTFLarge Cap / 15.9B market cap
CSPC Pharmaceutical Group Ltd
Compare
ALPMFLarge Cap / 26.4B market cap
Astellas Pharma Inc
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
Market Cap11.42B
P/E Ratio19.3179
Dividend Yield4.44%
Beta0.379
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.